Open the map

RevvityRVTY

Life science tools · NYSE · USA

$152.16
Down 0.9% todayClose

Up 58.8% this year and +34.6% since June 26, ahead of the life science sector at +10.7%. Revvity supplies 1 mapped company.

Market cap
$16.6B
This year
+58.8%
1 year
+68.4%
P/E
69.8
P/S
5.7
P/B
2.3

Price vs the life science sector

since Jun 26RVTYLife science sector, equal weight
Revvity (RVTY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. RVTY: +34.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%+40%Jun 26AugSepOct 8RVTY +34.6%Sector +10.7% Revvity (RVTY) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. RVTY: +34.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+20%+40%Jun 26AugSepOct 8RVTY+34.6%Sector+10.7%

Supply chain

1 customer
SUPPLIERS →→ CUSTOMERSNone mappedBristol Myers Squibb (BMY)BMYBristol Myers Squibb−0.2%RVTYRevvity

Customers 1

Open the full chain →

About Revvity

Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.

Theme exposure

Life science toolsNewborn screeningResearch reagents

Products

  • Newborn & genetic screening
  • Research reagents
  • Laboratory software

Competitors

Risks

  • Research budgets
  • Post-divestiture integration

Same segment: Life science tools

Instruments, reagents and equipment for research, development and production. Segment 5 of 8 in the Medicine, pharma & life science value chain.

Thermo Fisher ScientificTMO−1.5%DanaherDHR−0.5%Agilent TechnologiesA−0.5%Waters CorporationWAT−1.6%IlluminaILMN−1.2%

Compare RVTY

Side by side with the largest companies in the same segment.

RVTY vs TMORVTY vs DHRRVTY vs ARVTY vs WATRVTY vs ILMN

See where Revvity sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →